FGEN FibroGen Inc

47.21
+1.07  (+2%)
Previous Close 46.14
Open 46.33
Price To Book 7.93
Market Cap 4039400479
Shares 85,562,391
Volume 1,092,031
Short Ratio
Av. Daily Volume 691,732

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Pooled MACE safety data 1H 2019.
Roxadustat
Anaemia in Chronic Kidney Disease
Phase 3 data due 2020.
Roxadustat
Myelodysplastic syndromes (MDS)
Phase 2 initial data due end of 2Q 2019.
FG-3019
Duchenne muscular dystrophy
Phase 2 ongoing in Hong Kong. Future development uncertain
FG-3019
Liver fibrosis
Phase 3 trial to commence 2Q 2019.
Pamrevlumab (FG-3019)
Idiopathic pulmonary fibrosis
Phase 3 trial to be initiated 2Q 2019.
Pamrevlumab (FG-3019)
Pancreatic cancer
Phase 3 Japan data noted hepcidin reduction from baseline (p=0.003) compared to epoetin alfa group (p=0.12)
Roxadustat
Chronic kidney disease

Latest News

  1. FibroGen Receives Orphan Drug Designation from the U.S. FDA For Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
  2. Akebia Expands Vadadustat Licensing Deal With Vifor Pharma
  3. Is FibroGen, Inc. (NASDAQ:FGEN) A Financially Strong Company?
  4. Options Traders Expect Huge Moves in FibroGen (FGEN) Stock
  5. 4 Biotech Stocks With Major Catalysts in April
  6. FibroGen, Inc. (NASDAQ:FGEN): Commentary On Fundamentals
  7. What's in the Cards for Corbus (CRBP) This Earnings Season?
  8. Edited Transcript of FGEN earnings conference call or presentation 27-Feb-19 10:00pm GMT
  9. What Wall Street Recommends for Amarin after Q4 2018 Results
  10. FibroGen Inc (FGEN) Q4 2018 Earnings Conference Call Transcript
  11. FibroGen Reports Fourth Quarter and Full Year 2018 Financial Results
  12. What's in Store for Teladoc's (TDOC) Q4 Earnings?
  13. Tenet Healthcare (THC) Q4 Earnings: What's in the Offing?
  14. See what the IHS Markit Score report has to say about FibroGen Inc.
  15. How Much is FibroGen, Inc.’s (NASDAQ:FGEN) CEO Getting Paid?
  16. Today's Research Reports on Trending Tickers: Ligand Pharmaceuticals and FibroGen
  17. Analysis: Positioning to Benefit within Motorola Solutions, FibroGen, UnitedHealth Group, Newell Brands, Vuzix, and Choice Hotels International — Research Highlights Growth, Revenue, and Consolidated Results
  18. Can This Biotech Stock Rival Amgen In Anemia? Analyst Says Yes